Third-Quarter Financial Results
ABBVIE INC (NYSE:ABBV) has reported its financial results for the third quarter of 2025, revealing a mixed performance against analyst expectations. The company's leadership highlighted strong momentum across its portfolio and a raised quarterly cash dividend, though the underlying financial figures present a more nuanced picture.
Earnings and Revenue Performance
The company's earnings and revenue for the quarter ended September 30, 2025, showed notable deviations from Wall Street forecasts. While adjusted earnings per share surpassed expectations, reported revenue fell short of analyst projections.
- Adjusted EPS: Reported $1.86, which exceeded the analyst estimate of $1.8226.
- Total Revenue: Reported $15.78 billion, missing the analyst estimate of $15.90 billion.
On a GAAP basis, the results were significantly weaker, with diluted EPS plummeting to $0.10, a decrease of 88.6 percent compared to the prior year period. The adjusted diluted EPS of $1.86 also represents a 38.0 percent decline year-over-year, indicating persistent challenges despite the quarterly beat on the non-GAAP metric.
Market Reaction and Price Action
The immediate market reaction to the earnings release appears cautious. In pre-market trading, the stock is indicating a decline, which suggests investor focus may be centered on the revenue miss and the substantial year-over-year declines in profitability, overshadowing the adjusted EPS beat. This initial negative sentiment occurs within a broader context of weak recent performance for the stock.
- Pre-Market Performance: Down approximately 0.85%.
- Recent Trajectory: The stock has declined over the past month, showing a drop of about 3.5%.
Outlook and Analyst Estimates
In the press release, Chairman and CEO Robert A. Michael pointed to the "strength of our business and its promising outlook" as the rationale for once again raising the quarterly cash dividend. While the company did not provide specific quantitative financial guidance for the coming periods in the provided material, analyst estimates for the full year and the next quarter offer a benchmark for future performance.
Analyst expectations for the remainder of 2025 are as follows:
- Full-Year 2025 Estimated Revenue: $61.89 billion
- Q4 2025 Estimated Revenue: $16.65 billion
- Q4 2025 Estimated EPS: $3.39
The company's ability to meet or exceed these estimates in the next quarter will be critical in shifting market sentiment.
Press Release Summary
The core announcements from AbbVie's earnings press release centered on the declaration of continued business momentum and a commitment to returning capital to shareholders. Key management commentary emphasized progress in advancing the product pipeline and investing in innovation to secure long-term growth. The decision to raise the quarterly dividend was presented as a direct result of this confidence in the company's financial health and future prospects.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the data available on the AbbVie earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an offer to solicit any transaction in securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
